2023-06-28 11:38:08
Osteoarthritis, a common medical pathology that affects millions of people, has been the subject of research at SER-OARSI Symposium 2023, a meeting organized by the Spanish Society of Rheumatology where advances in biomarkers and personalized medicine have been explored to improve diagnosis and treatment of the disease.
The osteoarthritisa prevalent medical pathology in the population, stands out as the most common rheumatic disease. It affects approximately 30% of people over the age of 40, which is equivalent to about 242 million people worldwide.
“In spainabout 7 million individuals suffer from osteoarthritis, Galicia being responsible for some 900,000 cases. This condition is positioned as the third cause of incapacity for work and generates an annual cost of more than 12,000 euros per patient»affirms the Dr. Francisco Blancorheumatologist at the University Hospital Complex of A Coruña and president of the Scientific Committee of the ‘SER-OARSI Symposium 2023’an event that has brought together leading osteoarthritis specialists from around the world in A Coruña.
Osteoarthritis is closely linked to the aging, being this one of the main social determinants of health related to the disease. However, there are other important factors that contribute to the development of osteoarthritis, such as genetic predispositionthe obesity and the contact sports practicesuch as football, tennis and handball.
According to Dr. Blanco, the demographic agingthe increase in obesity and participation in contact sports are the three main reasons for the increase in osteoarthritis cases in recent years.
At SER-OARSI Symposium 2023, advances in biomarkers and personalized medicine have been explored to improve the diagnosis and treatment of the disease
He doctor Jose Antonio Pinto Tasenderepresentative of the Spanish Society of Rheumatology (TO BE) and rheumatologist at the University Hospital Complex of A Coruña, stresses that the osteoarthritis is almost 3 times more frequent in people with obesity compared to those with normal weight.
In the specific case of the knee osteoarthritis, this figure increases even more, becoming 5 times more common. The Strategy published by the Ministry of Health in Spain also points out the relationship between osteoarthritis of the knee and hip with obesity.
He muscle strengthening and ergonomic adjustments can influence the prevention of this disease. Furthermore, the practice of moderate and adapted physical exercise improves the evolution of osteoarthritis, by reducing pain, decreasing inflammation and increasing mobility. As pointed out by Dr. Pinto Tasende physical exercise from the age of 65 decreases frailty and the risk of falls.
Biomarkers to detect osteoarthritis in early stages
In the field of research, it seeks iidentify biomarkers that allow the detection of osteoarthritis in the initial stages and develop treatments that slow down its progression. In this context, the international experts gathered at the ‘SER-OARSI Symposium 2023’ They have shared the latest advances and explore possible ways of collaboration.
This symposium has analyzed the current situation of the personalized and precision medicine in the field of osteoarthritis, laying the foundations for its implementation in clinical practice. The clinical, imaging and molecular biomarkers are allowing an early diagnosis of osteoarthritis and the identification of new therapeutic targets, thus improving the available treatments. Furthermore, advances in artificial intelligencel are opening up new possibilities for applying personalized and precision medicine to patients with osteoarthritis.
Current research focuses on the early diagnosis of osteoarthritis, even before joint symptoms appear, such as pain, which is usually the reason for consultation. Also, it investigates the definition of endotypes and phenotypes of patientswhich will make it possible to find specific treatments and stop the progression of joint destruction caused by osteoarthritis.
Although putting a date on the discovery of a treatment “miraculous” for osteoarthritis it is difficult, the Dr White is optimistic and points out that there are currently several molecules in phase III developmenthence it is expected that in In the next 5 years, treatments will be available to stop osteoarthritis of the knee.
He Dr. Gun-ilpresident of the Osteoarthritis Research Society International (OARSI), shares this optimism and affirms that, thanks to the collaboration and efforts of researchers, advances in biomarkers and international meetings such as the ‘SER-OARSI Symposium’, concrete results will be achieved in the next ten years.
In this sense, although there is currently no clear consensus on the osteoarthritis biomarkersthese joint efforts are expected to bring important advances in the field of disease research and treatment.
1687952971
#Biomarkers #personalized #medicine #treat #osteoarthritis